Just less than half of the respondents worked in biotech companies, while a quarter worked in pharmaceutical companies and consultancies.
More than half of the respondents resided in North America, while most of the remaining respondents hailed from Europe and Asia.
Cell and gene therapies for oncology were the most common focus for a large proportion of our respondents, while a third of respondents said that their companies focused on rare diseases.
Autoimmune disorders and cardiovascular conditions were in third place, both a focus for the companies of 1 in 5 respondents.
Over half of the respondents worked in process development and manufacturing departments, and just under a quarter said that they worked in drug discovery and preclinical departments.
Gene therapy is the most popular product in companies’ pipelines, identified by more than half of applicable respondents.
CAR-T therapy was the next most common product, while 1 in 3 of the respondents said that their company was focusing on or planning to produce mesenchymal stem cell-based therapies.
